BackInter Pharma Public Company Limited Overview

Inter Pharma Public Company Limited Inventory

Track Inter Pharma Public Company Limited's inventory ($420M) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow
Inventory
$423.62M
↑ 22.74% YoYΔ $78.49M vs prior year quarter

Peer trimmed avg / median

Loading

Inter Pharma Public Company Limited Inventory History

Loading

Inter Pharma Public Company Limited vs. peers: Inventory Comparison

Loading

Inter Pharma Public Company Limited Inventory Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Inter Pharma Public Company Limited (IP.BK) FAQ

Inter Pharma Public Company Limited posts a inventory of $420M as of June 2026. That compares with $350M in the prior-year period — up 22.7% year over year. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

In the prior comparable period, Inter Pharma Public Company Limited's inventory was $350M. The latest reading is $420M — a 22.7% year-over-year increase (period ending June 2026). Use the history and growth charts on this page for a longer lookback.

Inventory is one piece of Inter Pharma Public Company Limited's financial statement story. At $420M, it should be interpreted next to related metrics — for example revenue with costs, assets with liabilities, or income with margins. Stockcircle links those related pages so you can move from this number to the surrounding context quickly.

Context for IP.BK's inventory usually means three checks: (1) trend versus prior periods, (2) level versus peers, and (3) consistency with growth and profitability. This page covers the first two; Inter Pharma Public Company Limited's other metric pages and overview cover the third.

Judging Inter Pharma Public Company Limited against Healthcare peers is usually better than using a market-wide rule of thumb. Business models inside Healthcare are more comparable, which makes gaps in inventory easier to interpret. Start with $420M here, then scan peer and history charts to see if the gap is persistent.